NCT03448731 (DERMIA) is a Phase 2 clinical trial of Doxycycline 50Mg Tablet in Skin Toxicity, sponsored by Fundacion CRIS de Investigación para Vencer el Cáncer.

Who is sponsoring NCT03448731?

NCT03448731 is sponsored by Fundacion CRIS de Investigación para Vencer el Cáncer.

What drugs are being tested in NCT03448731?

Interventions in NCT03448731: Doxycycline 50Mg Tablet.

What condition does NCT03448731 study?

NCT03448731 studies Skin Toxicity.

Is NCT03448731 still recruiting?

NCT03448731 is currently completed. Last updated 8 April 2020.

Last reviewed 2020-04-08 · How we verify

NCT03448731: DERMIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)

Completed Phase 2 Last updated 8 April 2020

What this trial tests

Phase 2 trial testing Doxycycline 50Mg Tablet in Skin Toxicity in 34 participants. Completed in 6 April 2020.

Timeline

10 May 2018

Primary endpoint
6 April 2020

6 April 2020

Quick facts

Lead sponsor	Fundacion CRIS de Investigación para Vencer el Cáncer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	10 May 2018
Primary completion	6 April 2020
Estimated completion	6 April 2020
Sites	8 locations across Spain

Drugs / interventions tested

Doxycycline 50Mg Tablet — full drug profile →

Conditions studied

Skin Toxicity — all drugs for Skin Toxicity →

Sponsor

Fundacion CRIS de Investigación para Vencer el Cáncer — full company profile →

Who can join

18 and older, any sex, with Skin Toxicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with anti-EGFR in combination with chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy.
Ramírez-Daffós P, Jiménez-Orozco E, Bolaños M, González Astorga B, et al · · 2022 · cited 6× · PMID 35776185 · DOI 10.1007/s00520-022-07254-5

Verify or expand the search:

Other recruiting trials for Skin Toxicity

Currently open trials in the same condition.

NCT04650256 — Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botani · NA · recruiting

Other Fundacion CRIS de Investigación para Vencer el Cáncer trials

Trials by the same sponsor.

NCT05022797 — Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS · Phase 2 · terminated
NCT04483505 — Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. · Phase 1 · completed
NCT03425201 — Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) · Phase 1, PHASE2 · completed
NCT03472274 — Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) · Phase 2 · completed
NCT03469661 — Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03448731 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundacion CRIS de Investigación para Vencer el Cáncer
Last refreshed: 8 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03448731.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing